Showing results (71-80 of 191) with videos related to
Sort By:
Pageof 20
Zeitschrift Fur Kardiologie|August 1, 1993
[Percutaneous transluminal coronary angioplasty in coronary multivessel disease: clinical course in relation to degree of functional revascularization]H Seggewiss, U Gleichmann, D Fassbender, et al.Deutsche Medizinische Wochenschrift (1946)|March 25, 1988
[Bradycardia factitia]S Eckert, H M Mertens, H Mannebach, et al.Deutsche Medizinische Wochenschrift (1946)|May 17, 1996
[Transvenous closure of persistent ductus arteriosus with an Ivalon plug]D Fassbender, H Seggewiss, H K Schmidt, et al.Clinical Cardiology|January 1, 1981
Influence of heart rate on systolic time intervals: effects of atrial pacing versus dynamic exerciseH M Mertens, H Mannebach, G Trieb, et al.Acta Medica Scandinavica|January 1, 1988
Intravenous thrombolytic treatment for acute myocardial infarction. Effects of early intervention and early examinationS Golf, P Vogt, U Kaufmann, et al.The New England Journal of Medicine|March 19, 1987
Intravascular stents to prevent occlusion and restenosis after transluminal angioplastyU Sigwart, J Puel, V Mirkovitch, et al.Singapore Medical Journal|June 29, 2004
A stent is not just a stent: Stent construction and design do matter in its clinical performanceK W Lau, A Johan, U Sigwart, et al.Singapore Medical Journal|February 24, 2001
Percutaneous interventional strategies in the treatment of chronic total coronary occlusionsK W Lau, Z P Ding, U Sigwart, et al.The Journal of Cardiovascular Surgery|June 1, 1993
Long term follow-up of Mitroflow pericardial valve prostheses in the small aortic annulusK Minami, S Schereika, H Körtke, et al.Journal of Molecular Medicine (Berlin, Germany)|October 1, 1995
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarctionW Prohaska, H Mannebach, M Schmidt, et al.Pageof 20